Originally published April 11.

Last week, just days after Myriad Genetics defended its BRCA patents before the federal circuit court of appeals in Association for Molecular Pathology et al. vs. the United States Patent and Trademark Office et al., the company announced a deal to develop a companion BRCA 1/2 test for BioMarin's PARP inhibitor BMN 673.

The agreement marks Myriad's third agreement to use its BRACAnalysis test as a companion diagnostic for a PARP inhibitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.